[Tissue inhibitor of metalloproteinases-1 level in patients with metabolic syndrome qualified for cardiac rehabilitation].
Each year in Poland, the number of patients treated by PCI and CABG increases. Many of them have metabolic syndrome. After these procedures patients are qualified for cardiac rehabilitation. It is preceded by risk stratification for cardiac events. Metalloproteinases belong to the enzymes responsible for destabilization of atheroma plaques. The activity of metalloproteinases is tightly regulated by their inhibitors. The aim of the study was to estimate plasma tissue inhibitor of metalloproteinases-1 (TIMP-1) level in patients with metabolic syndrome qualified for cardiac rehabilitation after PCI procedures. The study comprised of 50 subjects with metabolic syndrome (26 males, 24 females) aged 18-65 (mean 50.9+/-11.8) years, qualified for cardiac rehabilitation after PCI procedures and 25 healthy participants (13 males, 12 females) aged 21-55 (mean 50.2+/-12.8) years. The estimation of plasma TIMP-1 level was determined with use of R&D Systems kit. Plasma level of tissue inhibitor of metalloproteinases-1 in subjects with metabolic syndrome was 119.1+/-15.3 ng/ml and it was significantly lower than in group of healthy participants (188.5+/-14.7 ng/ml (p<0.001). Decreased plasma level of tissue inhibitor of metalloproteinases-1 in subjects with metabolic syndrome qualified for cardiac rehabilitation indicates disturbances of metalloproteinases activity control which take part in destabilization of atheroma plaque. In cardiac rehabilitation of subjects with metabolic syndrome we should pay attention to the type, time and intensity of exercise, because of increased risk of cardiovascular events.